Addition of chemotherapy to radiation therapy alters failure patterns by cell type within non-small cell carcinoma of lung (NSCCL): Analysis of radiation therapy oncology group (RTOG) trials

International Journal of Radiation Oncology Biology Physics

Volumn 43, Issue 3, 1999, Pages 505-509

  Cox, James D ^a   Scott, Charles B ^b   Byhardt, Roger W ^c   Emami, Bahman ^d   Russell, Anthony H ^e   Fu, Karen K ^f   Parliament, Matthew B ^g   Komaki, Ritsuko ^a   Gaspar, Laurie E W ^h  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b RTOG Headquarters   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Radiation Oncology Center   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF ALBERTA   (Canada)

^h WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adenocarcinoma; Chemotherapy; Lung; Neoplasms; Radiation therapy; Squamous cell carcinoma

Indexed keywords

ARTICLE; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; METASTASIS INHIBITION; METASTASIS POTENTIAL; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

ADENOCARCINOMA; ANALYSIS OF VARIANCE; BRAIN NEOPLASMS; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; HUMANS; LUNG NEOPLASMS; ODDS RATIO; PROSPECTIVE STUDIES; TREATMENT FAILURE;

EID: 0033011539     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(98)00429-5     Document Type: Article

References (22)

1. Parker S.L., Tong T., Bolden S., et al. Cancer statistics, 1997. CA: Cancer J Clin. 47:1997;5-27.
2. Cox J.D. Failure analysis in diagnostic and treatment strategies in cancer management. Cancer Treat Symp. 2:1983;1-3.
3. Komaki R., Scott C.B., Sause W.T., et al. Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable non-small cell lung cancer Failure patterns by cell type in RTOG 88-08/ECOG 4588 . Int J Radiat Oncol Biol Phys. 39:1997;527-544.
4. American Joint Committee on Cancer. Thorax. In: Beahrs OH, Henson DE, Hutter RVP, editors. Manual for staging of cancer. Philadelphia: JB Lippincott Company; 1992, p. 115-122.
5. Karnofsky D.A., Burchenal J.H. The clinical evaluation of chemotherapeutic agents in cancer. Macleod C.M. Evaluation of chemotherapeutic agents. 1949;191-205 Columbia University Press, New York.
6. Cox J.D., Azarnia N., Byhardt R.W., et al. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: Possible survival benefit with ≥69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: Report of Radiation Therapy Oncology Group 83-11. J Clin Oncol. 8:1990;1543-1555.
7. Asbell S.O., Pajak T., Seydel H.G., et al. Phase III RTOG double blind lung cancer trial of XRT and subsequent thymosin or placebo. Proc Am Soc Clin Oncol. 8:1990;242.
8. Russell A.H., Pajak T.E., Selim H.M., et al. Prophylactic cranial irradiation for lung cancer patients at high risk for development of cerebral metastasis Results of a prospective randomized trial conducted by the Radiation Therapy Oncology Group . Int J Radiat Oncol Biol Phys. 21:1991;637-643.
9. Byhardt R.W., Pajak T.F., Emami B., et al. A phase I/II study to evaluate accelerated fractionation via concomitant boost for squamous, adeno, and large cell carcinoma of the lung Report of Radiation Therapy Oncology Group 84-07 . Int J Radiat Oncol Biol Phys. 26:1993;459-468.
10. Sause W.T., Scott C., Taylor S., et al. Phase II trial of combination chemotherapy and irradiation in non-small-cell lung cancer. Radiation Therapy Oncology Group 88-04. Am J Clin Oncol. 15:1992;163-167.
11. Sause W.T., Scott C.B., Taylor S.G.I., et al. RTOG 88-08 and ECOG 4588 Preliminary results of a phase III trial in regionally advanced unresectable non-small cell lung cancer . J Natl Cancer Inst. 87:1995;198-205.
12. Byhardt R.W., Scott C.B., Ettinger D.S., et al. Concurrent hyperfractionated irradiation and chemotherapy for unresectable non-small cell lung cancer. Results of Radiation Therapy Oncology Group (RTOG) 90-15. Cancer. 75:1995;2337-2344.
13. Lee J.S., Scott C., Komaki R., et al. Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small cell lung cancer Radiation Therapy Oncology Group protocol 91-06 . J Clin Oncol. 14:1996;1055-1064.
14. Komaki R., Scott C., Ettinger D., et al. Randomized study of chemotherapy/radiation therapy combinations for favorable patients with locally advanced inoperable nonsmall cell lung cancer Radiation Therapy Oncology Group (RTOG) 9204 . Int J Radiat Oncol Biol Phys. 38:1997;149-155.
15. Yesner R., Seydel G.H., Asbell S.O., et al. Biopsies of non-small cell lung cancer Central review in cooperative studies of the Radiation Therapy Oncology Group . Mod Pathol. 4:1991;432-435.
16. Mehta C., Patel N. StatXact. 1992;CYTEL Software, Cambridge.
17. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481.
18. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chem Rep. 50:1966;163-170.
19. Hyde L., Hyde C.I. Clinical manifestations of lung cancer. Chest. 65:1974;299-306.
20. Saunders M.I., Dische S., Barrett A., et al. Randomised multicentre trials of CHART vs. conventional radiotherapy in head and neck and non-small-cell lung cancer An interim report . Br J Cancer. 73:1996;1455-1462.
21. Komaki R., Morice R.C., Walsh G.L. High-dose-rate remote afterloading endobronchial brachytherapy. Roth J.A., Cox J.D., Hong W.K. Lung cancer. 2nd ed. 1998;163-179 Blackwell Science, Oxford.
22. Roth J.A., Nguyen D., Lawrence D.D., et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nature Med. 2:1996;985-991.